Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes. The approval makes ...
Novo won the U.S. Food and Drug Administration's approval in 2024 to use Wegovy to reduce the risk of cardiovascular death, ...
(Reuters) -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and ...
Novo Nordisk said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros for up to $2.1 billion. Under the asset purchase ...
Weight loss drugs like Ozempic and Wegovy can be used for a variety of other conditions, such as Alzheimer's, alcohol ...
Novo Nordisk's older semaglutide version didn't meet expectations in trials to slow Alzheimer's cognitive decline. This ...
The share price of Danish pharmaceutical giant Novo Nordisk ( NVO +1.31%) hit a four-year low Monday, falling below $44 a ...
Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on ...
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. Shortly after market close ...
The drug tested was Rybelsus, a pill approved only for type 2 diabetes. Like Novo's blockbusters Ozempic and Wegovy, it ...
Novo Nordisk NOVO.B-3.02%decrease; red down pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback